On March 6, Sciwind Biosciences and Pfizer announced that their cAMP-biased GLP-1 receptor agonist ecnoglutide had been approved in China for a new indication, for long-term weight management in adult patients on the basis of diet control and increased physical activity.
Ecnoglutide injection, development code XW003 and formerly known as inoglutide, is a globally first-in-class long-acting cAMP-biased GLP-1 receptor agonist independently developed by Sciwind Biosciences. According to the Insight database, ecnoglutide was first publicly disclosed for clinical development in March 2020 and first approved in China in January 2026 for type 2 diabetes. This new approval is the second indication for the drug.
It is worth noting that in February 2026, Pfizer and Sciwind Biosciences entered into a commercialization strategic cooperation agreement worth nearly USD 500 million for ecnoglutide injection, under which Pfizer obtained exclusive commercialization rights for the product in mainland China.
According to the Insight database, in addition to the injectable formulation, Sciwind is also developing an oral tablet formulation of ecnoglutide, XW004, which has already entered Phase II clinical development.
Ecnoglutide injection currently has seven Phase III clinical trials on record, three of which have already reported results, including the EECOH-1 and EECOH-2 studies supporting approval in type 2 diabetes and the SLIMMER study for the obesity indication.
The clinical results of the SLIMMER trial have been published in The Lancet Diabetes & Endocrinology and were also presented in an oral session at the 2025 Scientific Sessions of the American Diabetes Association.
This was a multicenter, randomized, double-blind, placebo-controlled Phase III clinical trial that enrolled 664 patients with obesity, defined as BMI at least 28 kg/m², or overweight, defined as BMI at least 24 kg/m² and below 28 kg/m², with at least one weight-related comorbidity. Patients were randomly assigned to receive ecnoglutide 1.2 mg, 1.8 mg, or 2.4 mg once weekly, or placebo, for a total treatment duration of 48 weeks. The primary endpoints were percentage change in body weight from baseline at Week 40 and the proportion of subjects achieving at least 5% reduction in body weight from baseline.
Based on the estimand for the treatment policy strategy, ecnoglutide produced dose-dependent weight reduction at Week 40:
In the highest-dose group of 2.4 mg, mean body weight decreased by 13.2% from baseline, while the placebo group increased by 0.1%, with p<0.0001. By Week 48, weight reduction further increased to 15.4%, or 15.1% after placebo correction.
Among participants, 92.8% achieved clinically meaningful weight loss of at least 5%, about seven times the rate in the placebo group.
In addition, 79.6% and 63.5% of subjects achieved at least 10% and at least 15% weight reduction, respectively, exceeding results reported for other non-biased GLP-1 receptor agonists in similar populations.
Beyond significant weight reduction, the ecnoglutide group also significantly improved other key cardiometabolic risk indicators. In addition, mean uric acid levels decreased by as much as 54.3 micromol/L, and the incidence of hyperuricemia was lower than in the placebo group.
Notably, ecnoglutide also significantly reduced liver fat content. In subjects with baseline liver fat content of at least 8%, the average percentage change from baseline at Week 40 in the 2.4 mg ecnoglutide group reached minus 53.1%. Liver enzyme levels were also significantly lower than in the placebo group across all dose groups.
Metabolic drugs led by GLP-1 have gained strong momentum in recent years, driving leading companies in the field to new heights. In 2025, Novo Nordisk’s semaglutide achieved global sales of USD 34.608 billion, while Lilly’s tirzepatide recorded USD 36.507 billion and became the top-selling drug.
In China, according to the Insight database, 12 GLP-1 receptor agonist innovative drugs have now been approved. Aside from Lilly’s tirzepatide and Innovent’s mazdutide, all the others are single-target drugs. As an innovative cAMP-biased GLP-1 receptor agonist, ecnoglutide may secure a place in this highly competitive market.